Stock comparison
Eli Lilly
Telix Pharmaceuticals Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
TLX
Telix Pharmaceuticals Limited
Market cap
$3.21B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | TLX | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 31F | LLY |
| Benjamin Graham | 86A | 49D | LLY |
| Philip Fisher | 86A | 50C | LLY |
| Peter Lynch | 74B | 29F | LLY |
| Joel Greenblatt | 78C | 0F | LLY |
| Charlie Munger | 85A | 44D | LLY |
| Terry Smith | 77C | 38D | LLY |
Side-by-side metrics
| Metric | LLY | TLX |
|---|---|---|
| Market cap | $1T | $3.21B |
| P/E (TTM) | 36.6x | - |
| EV/EBIT | 34.1x | 211.6x |
| ROIC (TTM) | 32.06% | 1.77% |
| Gross margin | 83.51% | 50.76% |
| Net margin | 34.98% | -0.89% |
| Revenue CAGR 5y | 23.17% | 2.55% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 1.3x |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Net margin34.98%vs -0.89%+103%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $3.21B+100%
- ROIC (TTM)32.06%vs 1.77%+94%
TLX leads on
- P/E (TTM)-vs 36.6x+108%
- Revenue CAGR 5y2.55%vs 23.17%+91%
- Debt / Equity1.3xvs 1.4x+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.